Dr. Andrew Bukowinski
Claim this profileChildren's Hospital of Pittsburgh of UPMC
Studies Tumors
Studies Recurrence
24 reported clinical trials
38 drugs studied
About Andrew Bukowinski
Education:
- Earned an MD from the University of Pittsburgh School of Medicine in 2015.
- Completed Residency in Pediatrics at the Children's Hospital of Pittsburgh of UPMC in 2018.
- Completed Fellowship in Pediatric Cardiology at the Children's Hospital of Pittsburgh of UPMC in 2021.
Experience:
- Serving as an Attending Physician in Pediatric Cardiology at the Children's Hospital of Pittsburgh of UPMC since 2021.
Area of expertise
1Tumors
Stage IV
NTRK1 positive
NTRK positive
2Recurrence
Stage IV
Philadelphia chromosome positive
CD22 positive
Affiliated Hospitals
Clinical Trials Andrew Bukowinski is currently running
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting1 award Phase 1 & 213 criteria
DAY101
for Langerhans Cell Histiocytosis
This trial tests the safety and effectiveness of tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis that is worsening, has returned, or does not respond to other treatments. Tovorafenib is taken orally and works by blocking enzymes needed for cancer cell growth. The study aims to find the best dose and observe the response and side effects over time.
Recruiting1 award Phase 228 criteria
More about Andrew Bukowinski
Clinical Trial Related8 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Andrew Bukowinski has experience with
- Ramucirumab
- Gemcitabine
- Cyclophosphamide
- Nivolumab
- Docetaxel
- Vinorelbine
Breakdown of trials Andrew Bukowinski has run
Tumors
Recurrence
Leukemia
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew Bukowinski specialize in?
Andrew Bukowinski focuses on Tumors and Recurrence. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are NTRK1 positive.
Is Andrew Bukowinski currently recruiting for clinical trials?
Yes, Andrew Bukowinski is currently recruiting for 10 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Andrew Bukowinski has studied deeply?
Yes, Andrew Bukowinski has studied treatments such as Ramucirumab, Gemcitabine, Cyclophosphamide.
What is the best way to schedule an appointment with Andrew Bukowinski?
Apply for one of the trials that Andrew Bukowinski is conducting.
What is the office address of Andrew Bukowinski?
The office of Andrew Bukowinski is located at: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania 15224 United States. This is the address for their practice at the Children's Hospital of Pittsburgh of UPMC.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.